Characterization of Patients Responding to Enfortumab Vedotin Plus Pembrolizumab (EV+P): Exploratory Analysis From the Phase 3 EV-302 Trial of EV+P versus Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)